- FzioMed, Inc.
- Skye Biologics Inc
- IOP Ophthalmics
- Amniox Medical, Inc.
- Amnio Technology, LLC
- Applied Biologics LLC
- Alliqua BioMedical, Inc.
- Human Regenerative Technologies, LLC
- Derma Sciences Inc.
- MiMedx Group, Inc.
- AlloCure
- Bellicum Pharmaceuticals
- Biogen Idec
- BIOTIME
- Bone Therapeutics
- Cell Medica
- CESCA THERAPEUTICS
- Fibrocell Science
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Amniotic Membrane Market:
In January 2022, One of the top independent pharmaceutical firms in Europe, Laboratoires Thea SAS, signed a contract to buy seven branded ophthalmic products from Akorn Operating Company LLC, including AcellFX, which offers a protective environment or covering for ocular surface repair.
The amniotic membrane is a thin layer of tissue that surrounds the fetus during pregnancy. It is rich in growth factors, cytokines, and extracellular matrix proteins that have been shown to have regenerative properties. The use of amniotic membrane in various medical applications, including ophthalmology, wound healing, and orthopedics, has been increasing in recent years. The amniotic membrane market is primarily driven by the rising geriatric population, the increasing prevalence of chronic diseases, and the advancements in regenerative medicine. The demand for amniotic membrane in ophthalmology, wound healing, and orthopedics is expected to grow in the coming years, as it has been shown to promote tissue regeneration, reduce inflammation, and improve healing outcomes. Additionally, the increasing adoption of minimally invasive surgical procedures is expected to drive market growth, as amniotic membrane can be easily applied using minimally invasive techniques, such as injection or grafting.
However, the high cost of amniotic membrane products, lack of reimbursement policies, and ethical concerns regarding the collection of amniotic membrane are some of the major challenges faced by the market. Additionally, the COVID-19 pandemic has also impacted the market dynamics, with supply chain disruptions and reduced demand for elective procedures.
Despite these challenges, the amniotic membrane market is expected to grow throughout the forecast period, driven by the increasing investment in research and development activities to develop innovative products and the rising demand for regenerative medicine. Moreover, the increasing adoption of telemedicine and other digital health technologies is expected to improve the accessibility and delivery of amniotic membrane products to patients in remote areas. Thus, it is projected to drive the market growth in the coming years.